Name: A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate (NMDA) Receptor in Blood (Video) | JoVE Journal
Uploaded: 2018-01-09T13:00:00.000+00:00
Duration: 7 min 20 s
Description: Learn a cell-based immunofluorescence assay to detect NMDA receptor autoantibodies in blood using HEK293 cells expressing NR1-GFP. This method provides a simple screening tool for autoimmune encephalitis diagnosis.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was supported by the Chang Gung Medical Foundation (grant number CMRPG3C1771, CMRPG3C1772, CMRPG3E0631, CMRPG3E0632, and CMRPG3E0633).

The study was approved by the Institutional Review Board of Chang Gung Memorial Hospital at Linkuo, Taoyuan, Taiwan (102-2577A3).
1. Preparation of the NR1-GFP Expression Plasmid
<ol>
	<li>Mix 10 ng of NR1-GFP plasmid with 100 &#181;L of Escherichia coli competent cells strain DH5&#945; in a sterile 1.5 mL centrifuge tube, pipet the mixture gently up and down 4-6 times, and incubate the tube on ice for 20 min.</li>
	<li>Incubate the tube at 42 &#176;C for 1 min in a water bath, remove the tube from the water bath, add 1 mL lysogeny broth (LB) medium into the tube, and incubate the tube at 37 &#176;C in an incubator with shaking for 1 h.</li>
	<li>Spread 50 &#181;L of the mixture onto an LB agar plate containing ampicillin (0.1 mg/mL), and incubate the LB agar plate at 37 &#176;C in an incubator overnight.</li>
	<li>Pick a single colony from the overnight LB agar plate using a sterile tip, and swirl the tip in a in a bacterial culture tube containing 5 mL of LB medium and ampicillin (0.1 mg/mL). Incubate the tube at 37 &#176;C in an incubator with shaking overnight.</li>
	<li>Aliquot 3 mL of the overnight bacterial culture into a 500 mL flask that contains 250 mL sterile LB medium and ampicillin (0.1 mg/mL). Incubate the flask at 37 &#176;C with shaking. Check regularly the optic density (OD) of the bacterial culture at wavelength of 600 nm using a spectrometer until the OD600 reaches 0.6-1.0. 
	NOTE: Mix well 800 &#181;L of the overnight bacterial culture with 200 &#181;L glycerol to prepare the glycerol stock, and store the glycerol stock under -80 &#176;C for future use.</li>
	<li>Prepare NR1-GFP expression plasmid from the 250 mL bacterial culture
	<ol>
		<li>Collect the cells by centrifugation at 6,000 x g for 15 min at 4 &#176;C.</li>
		<li>Resuspend the bacteria pellet in 10 mL resuspension buffer containing RNase A; vortex thoroughly until no clump is seen.</li>
		<li>Add 10 mL lysis buffer to the bacterial suspension, gently invert the mixture 4-6 times, and incubate the lysate at room temperature (RT) for 5 min.</li>
		<li>Add 10 mL pre-chilled precipitation buffer to the lysate, gently invert the mixture 4-6 times.</li>
		<li>Pour the lysate into the barrel of a filter cartridge with the cap on; wait for 10 min at RT.</li>
		<li>Remove the cap from the cartridge outlet nozzle, insert a plunger into the cartridge, and gently press the plunger. Collect the filtered lysate into a 50 mL tube.</li>
		<li>Add 2.5 mL proprietary buffer from the manufacturer to the filtered lysate, mix the mixture by inverting the tube approximately 10 times, and incubate the mixture on ice for 30 min.</li>
		<li>Apply the filtered lysate mixture to a filter column that was pre-equilibrated with 10 mL equilibration buffer. Allow the column to drain by gravity.</li>
		<li>Wash the column with 30 mL wash buffer twice, then elute DNA from the column using 15 mL elution buffer.</li>
		<li>Add 10.5 mL (0.7 volumes) isopropanol to the eluted DNA buffer, mix well, and centrifuge the mixture at 20,000 x g for 30 min at 4 &#176;C.</li>
		<li>Decant the supernatant carefully, wash the DNA pellet with 5 mL endotoxin-free 70% ethanol once, and centrifuge at 20,000 x g for 10 min.</li>
		<li>Decant the supernatant, dry the pellet for 5-10 min in a chemical hood, and dissolve the pellet in 300-500 &#181;L of endotoxin-free buffer.</li>
		<li>Determine the plasmid concentration by measuring the absorption of the solution at UV 260/280 nm using a spectrophotometer. 
		NOTE: Prepare the expression plasmid GFP using the same protocol.</li>
	</ol>
	</li>
</ol>
2. Transfection of HEK293 Cells with NR1-GFP Expression Plasmid
<ol>
	<li>Aliquot 200 &#181;L of 2% gelatin solution to each well of a 48-well culture plate and incubate the plate at 37 &#176;C for at least 30 min.</li>
	<li>Aspirate the gelatin solution from the well, and seed 5 x 104 HEK293 cells in 200 &#181;L of cell culture medium containing 10% fetal bovine serum (FBS) in each well. Incubate the plate at 37 &#176;C in a humidified incubator supplied with 5% CO2 overnight. 
	NOTE: Cells were counted using a hemocytometer.</li>
	<li>On the next day, replace the spent culture medium with 200 &#181;L of fresh culture medium containing 10% FBS per well.</li>
	<li>For each single well, prepare solution A by mixing 100 ng of NR1-tGFP plasmid with 20 &#181;L culture medium, and solution B by mixing 0.8 &#181;L transfection reagent with 20 &#181;L culture medium. Multiply the number of wells needed to prepare the total volume for each experiment.</li>
	<li>Prepare solution C by mixing solution A and solution B, and incubate the mixture at RT for 20-30 min.</li>
	<li>Aliquot 40 &#181;L of solution C to each well containing the HEK293 cells, swirl the plate gently, and incubate the plate at 37 &#176;C in a humidified incubator supplied with 5% CO2 overnight.</li>
	<li>Check the expression of NR1-GFP recombinant protein in the host cells under fluorescent microscope with 40X-200X magnification (excitation/emission: 482/502 nm), and proceed to the cell-based immunofluorescence assay. 
	NOTE: Transfect the expression plasmid GFP into the HEK293 cells using the same protocol.</li>
</ol>
3. Cell-based Immunofluorescence Assay
<ol>
	<li>Aspirate the spent medium from the wells, then wash each well with 200 &#181;L of phosphate buffered saline (PBS) three times.</li>
	<li>Add 200 &#181;L of 4% paraformaldehyde solution to each well; incubate the plate at RT for 15 min.</li>
	<li>Aspirate the paraformaldehyde solution from the wells, and wash each well with 200 &#181;L of PBS three times.</li>
	<li>Add 200 &#181;L of 10% skim milk in PBST (0.1% Tween-20 in PBS) solution to each well, and incubate the plate at RT for 1 h with gentle shaking.</li>
	<li>Aspirate the 10% skim milk in PBST solution from the well, then wash the wells with 200 &#181;L PBST once.</li>
	<li>Incubate the wells with diluted plasma (1:100 in PBST) as the primary antibody with gentle shaking at RT for 1 h. 
	NOTE: Plasma is obtained from the blood of patients suspected to have autoimmune encephalitis.</li>
	<li>Aspirate the diluted plasma from the wells, and wash each well with 200 &#181;L of PBST three times.</li>
	<li>Add 200 &#181;L of goat anti-human IgG conjugated with Alexa Fluor 594 (1:1,000 dilution in PBST) to each well, and incubate the culture plate at RT with gentle shaking for 1 h.</li>
	<li>Aspirate the goat anti-human IgG conjugated with Alexa Fluor 594 solution, and wash each well with 200 &#181;L of PBST three times.</li>
	<li>Add 100 &#181;L glycerol solution (50% glycerol in PBS and 1:100,000 of 4&#39;,6-diamidino-2-phenylindole (DAPI)) to each well.</li>
	<li>Observe and image the cells under a fluorescent microscope using a 10X eyepiece, and 4X, 10X, and 20X objectives. 
	NOTE: Use the correct filter for each dye: for NR1-GFP (excitation/emission = 482/502 nm), for Alexa Fluor 594 (excitation/emission = 561/594 nm), for DAPI (excitation/emission = 358/461 nm). Conduct the negative control using the HEK cells expressing GFP in the same way.</li>
</ol>

<ol><li>Linnoila, J. J., Rosenfeld, M. R., Dalmau, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Neuronal+surface+antibody-mediated+autoimmune+encephalitis%5BTitle%5D)+AND+%22Semin+Neurol%22%5BJournal%5D)">Neuronal surface antibody-mediated autoimmune encephalitis.</a> Semin Neurol. 34 (4), 458-466 (2014).</li>
<li>Lancaster, E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+diagnosis+and+treatment+of+autoimmune+Encephalitis%5BTitle%5D)+AND+%22J+Clin+Neurol%22%5BJournal%5D)">The diagnosis and treatment of autoimmune Encephalitis.</a> J Clin Neurol. 12 (1), 1-13 (2016).</li>
<li>Pruss, H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Retrospective+analysis+of+NMDA+receptor+antibodies+in+encephalitis+of+unknown+origin%5BTitle%5D)+AND+%22Neurology%22%5BJournal%5D)">Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin.</a> Neurology. 75 (19), 1735-1739 (2010).</li>
<li>Leypoldt, F., Armangue, T., Dalmau, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Autoimmune+encephalopathies%5BTitle%5D)+AND+%22Ann+N+Y+Acad+Sci%22%5BJournal%5D)">Autoimmune encephalopathies.</a> Ann N Y Acad Sci. 1338, 94-114 (2015).</li>
<li>Dalmau, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Anti-NMDA-receptor+encephalitis%3A+case+series+and+analysis+of+the+effects+of+antibodies%5BTitle%5D)+AND+%22Lancet+Neurol%22%5BJournal%5D)">Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies.</a> Lancet Neurol. 7 (12), 1091-1098 (2008).</li>
<li>Titulaer, M. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Treatment+and+prognostic+factors+for+long-term+outcome+in+patients+with+anti-NMDA+receptor+encephalitis%3A+an+observational+cohort+study%5BTitle%5D)+AND+%22Lancet+Neurol%22%5BJournal%5D)">Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.</a> Lancet Neurol. 12 (2), 157-165 (2013).</li>
<li>Chapman, M. R., Vause, H. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Anti-NMDA+receptor+encephalitis%3A+diagnosis%2C+psychiatric+presentation%2C+and+treatment%5BTitle%5D)+AND+%22Am+J+Psychiatry%22%5BJournal%5D)">Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment.</a> Am J Psychiatry. 168 (3), 245-251 (2011).</li>
<li>Gable, M., Glaser, C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Anti-n-methyl-d-aspartate+receptor+encephalitis+appearing+as+a+new-onset+psychosis%3A+disease+course+in+children+and+adolescents+within+the+california+encephalitis+project%5BTitle%5D)+AND+%22Pediatr+Neurol%22%5BJournal%5D)">Anti-n-methyl-d-aspartate receptor encephalitis appearing as a new-onset psychosis: disease course in children and adolescents within the california encephalitis project.</a> Pediatr Neurol. 72, 25-30 (2017).</li>
<li>Dalmau, J., Lancaster, E., Martinez-Hernandez, E., Rosenfeld, M. R., Balice-Gordon, R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Clinical+experience+and+laboratory+investigations+in+patients+with+anti-NMDAR+encephalitis%5BTitle%5D)+AND+%22Lancet+Neurol%22%5BJournal%5D)">Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis.</a> Lancet Neurol. 10 (1), 63-74 (2011).</li>
<li>Dalmau, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Paraneoplastic+anti-N-methyl-D-aspartate+receptor+encephalitis+associated+with+ovarian+teratoma%5BTitle%5D)+AND+%22Ann+Neurol%22%5BJournal%5D)">Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma.</a> Ann Neurol. 61 (1), 25-36 (2007).</li>
<li>Irani, S. R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((N-methyl-D-aspartate+antibody+encephalitis%3A+temporal+progression+of+clinical+and+paraclinical+observations+in+a+predominantly+non-paraneoplastic+disorder+of+both+sexes%5BTitle%5D)+AND+%22Brain%22%5BJournal%5D)">N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes.</a> Brain. 133 (Pt 6), 1655-1667 (2010).</li>
<li>Suh-Lailam, B. B., Haven, T. R., Copple, S. S., Knapp, D., Jaskowski, T. D., Tebo, A. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Anti-NMDA-receptor+antibody+encephalitis%3A+performance+evaluation+and+laboratory+experience+with+the+anti-NMDA-receptor+IgG+assay%5BTitle%5D)+AND+%22Clin+Chim+Acta%22%5BJournal%5D)">Anti-NMDA-receptor antibody encephalitis: performance evaluation and laboratory experience with the anti-NMDA-receptor IgG assay.</a> Clin Chim Acta. 421, 1-6 (2013).</li>
<li>Mayer, M. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Structural+biology+of+glutamate+receptor+ion+channel+complexes%5BTitle%5D)+AND+%22Curr+Opin+Struct+Biol%22%5BJournal%5D)">Structural biology of glutamate receptor ion channel complexes.</a> Curr Opin Struct Biol. 41, 119-127 (2016).</li>
<li>Ramberger, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Comparison+of+diagnostic+accuracy+of+microscopy+and+flow+cytometry+in+evaluating+n-methyl-d-aspartate+receptor+antibodies+in+serum+using+a+live+cell-based+assay%5BTitle%5D)+AND+%22PLoS+One%22%5BJournal%5D)">Comparison of diagnostic accuracy of microscopy and flow cytometry in evaluating n-methyl-d-aspartate receptor antibodies in serum using a live cell-based assay.</a> PLoS One. 10 (3), e0122037(2015).</li>
<li>Wandinger, K. P., Saschenbrecker, S., Stoecker, W., Dalmau, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Anti-NMDA-receptor+encephalitis%3A+a+severe%2C+multistage%2C+treatable+disorder+presenting+with+psychosis%5BTitle%5D)+AND+%22J+Neuroimmunol%22%5BJournal%5D)">Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis.</a> J Neuroimmunol. 231 (1-2), 86-91 (2011).</li>
<li>Dahm, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Seroprevalence+of+autoantibodies+against+brain+antigens+in+health+and+disease%5BTitle%5D)+AND+%22Ann+Neurol%22%5BJournal%5D)">Seroprevalence of autoantibodies against brain antigens in health and disease.</a> Ann Neurol. 76 (1), 82-94 (2014).</li>
<li>Jézéquel, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cell-+and+single+molecule-based+methods+to+detect+anti-n-methyl-d-aspartate+receptor+autoantibodies+in+patients+with+first-episode+psychosis+from+the+OPTiMiSE+project%5BTitle%5D)+AND+%22Biol+Psychiatry%22%5BJournal%5D)">Cell- and single molecule-based methods to detect anti-n-methyl-d-aspartate receptor autoantibodies in patients with first-episode psychosis from the OPTiMiSE project.</a> Biol Psychiatry. , (2017).</li>
</ol>

The authors have nothing to disclose.

There are several cell-based immunological assays to screen the presence of autoantibodies against NMDA receptor reported in the literature, including live cell-based immunofluorescence assay11, fixed cell-based immunofluorescence assay9, and flow cytometry-based assay14. The live cell-based immunofluorescence assay should be performed shortly after the preparation of cells ectopically expressing the NR1 protein, while the flow cytometry-based assay ...

Anti-NMDA receptor autoimmune encephalitis is a newly recognized disease entity that can occur in patients of all ages, and affects predominantly female patients1,2. It is one of the most frequently diagnosed encephalitis among patients with initial unknown etiology of encephalitis3. Patients affected with anti-NMDA receptor encephalitis usually have prodromal symptoms of a headache or fever, followed by the quick development of consciousness level change and a variety of acute neuropsychiatric symptoms, including agitation, irritability, anxiety, insomnia, hallucinations, delusions, aggression, bizarre behaviors, movement abnormalities, autonomic dysregulation, and seizure attacks4,5. Early recognition of this condition and timely treatment with immunotherapy are important for a better outcome and even full recovery in affected patients6. Hence, it is suggested that anti-NMDA receptor autoimmune encephalitis should be considered as an important differential diagnosis of patients presenting with acute or new-onset psychotic features7,8.
Besides clinical features, detection of autoantibody against the NMDA receptor in the blood or CSF is essential for the accurate diagnosis of anti-NMDA receptor autoimmune encephalitis9. Most of the immunological tests to detect the anti-NMDA receptor autoantibody are available in a few research laboratories10,11, and there is only one commercially available cell-based immunofluorescence assay for screening the anti-NMDA receptor autoantibodies12. The goal of this study is to develop a simple in-house cell-based immunofluorescence assay that can be conveniently used in the laboratory to screen the presence of anti-NMDA receptor autoantibodies to facilitate the clinical research of anti-NMDA receptor autoimmune encephalitis. The NMDA receptor is a heterotetramer ion channel protein complex specifically expressed in the brain. It is made of two compulsory NR1 subunits, and the combination of one or two subunits of NR2A, NR2B, NR2C, or NR2D13. A previous study reported that the main epitope targeted by the antibodies was at the extracellular N-terminal domain of the NR1 subunit5. Hence, in this protocol, we express the human recombinant NR1-subunit protein of NMDA receptor tagged with green fluorescent protein (GFP) in the human embryonic kidney epithelial cell line (HEK293), and develop a cell-based immunofluorescence assay to detect the IgG class of anti-NMDA receptor autoantibodies in the blood.

<table><tbody><tr><td>GRIN1 (GFP-tagged) - Human glutamate receptor, ionotropic, N-methyl D-aspartate 1 (GRIN1), transcript variant NR1-1</td><td>Origene (Rockville, MD, USA)</td><td>RG219368</td><td>NR1-cDNA clone tagged with C-terminal tGFP sequences</td></tr><tr><td>pCMV6-AC-GFP</td><td>Origene (Rockville, MD, USA)</td><td>PS100010</td><td>mammalian vector with C-terminal tGFP tag</td></tr><tr><td>EndoFree Plasmid Maxi Kit</td><td>Qiagen (Hilden Germany)</td><td>12362</td><td></td></tr><tr><td>Lipofectamine 2000 Transfection Reagent</td><td>Invitrogen (Carlsbad, CA, USA)</td><td>11668-019</td><td></td></tr><tr><td>Opti-MEM I Reduced Serum Medium</td><td>Thermo Fisher</td><td>31985-070</td><td></td></tr><tr><td>DMEM, High Glucose, Pyruvate</td><td>Thermo Fisher</td><td>11995-065</td><td></td></tr><tr><td>Characterized Fetal Bovine Serum, US Origin</td><td>GE Healthcare Life Sciences</td><td>SH30071.01</td><td></td></tr><tr><td>Goat anti-Human IgG (H+L) Secondary Antibody, Alexa Fluor 594 conjugate</td><td>Thermo Fisher</td><td>A-11014</td><td></td></tr><tr><td>Positive control: anti-glutamate receptor (type NMDA)</td><td>Euroimmun AG, L&amp;uuml;beck, Germany</td><td>CA 112d-0101</td><td></td></tr><tr><td>Euroimmun Assay Kit</td><td></td><td></td><td></td></tr></tbody></table>

a simple cell-based immunofluorescence assay to detect autoantibody against the n-methyl-d-aspartate (nmda) receptor in blood

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate (NMDA) Receptor in Blood

The presence of anti-NMDA receptor autoantibody can cause various neuropsychiatric symptoms in the affected patients, termed anti-NMDA receptor autoimmune encephalitis. Detection of the specific autoantibody against the NMDA receptor in the blood or cerebrospinal fluid (CSF) is essential for the accurate diagnosis of this condition. The NMDA receptor is an ion channel protein complex that contains four subunits, including two mandatory NMDA receptor subunit 1 (NR1) and one or two NMDA receptor subunit 2A (NR2A), NMDA receptor subunit 2B (NR2B), NMDA receptor subunit 2C (NR2C), or NMDA receptor subunit 2D (NR2D). The epitope of anti-NMDA receptor autoantibody was reported to be present at the extracellular N-terminal domain of the NR1 subunit of the NMDA receptor. The goal of this study is to develop a simple cell-based immunofluorescence assay that can be used as a screening test to detect the presence of autoantibodies against NR1 subunit of the NMDA receptor in the blood to facilitate the clinical and basic research of anti-NMDA receptor autoimmune encephalitis.

On average, we could obtain 200-300 µg endotoxin-free expression plasmid NR1-GFP and GFP from 250 mL bacterial culture following the procedures described in section 1 of the protocol. An amount of 100 ng/well of the expression plasmid was used for the transfection of the HEK293 cells cultured in the 48-well plate as described in the section 2 of the protocol. 24-30 h after transfection, the cells expressed the NR1-GFP, and GFP recombinant proteins could be detected under fluorescent micro...

We ectopically expressed NR1 subunit of NMDA receptor tagged with green fluorescent protein in human embryonic cells (HEK293) as antigen to detect autoantibodies against NMDA receptor in the blood of patients suspected with autoimmune encephalitis. This simple method may be suitable for screening purposes in clinical settings.

The presence of anti-NMDA receptor autoantibody can cause various neuropsychiatric symptoms in the affected patients, termed anti-NMDA receptor autoimmune ...

a-simple-cell-based-immunofluorescence-assay-to-detect-autoantibody

Research

JoVE Journal

Neuroscience

This video demonstrates a technique for identifying antibodies against specific antigens in a sample using a rat hippocampal neuronal culture. By exposing cultured neurons to patient samples containing autoantibodies targeting N-Methyl-D-aspartate receptors (NMDARs), the presence of autoantibodies bound to the neuronal surface is revealed through immunostaining.

An Assay to Detect Autoantibodies in Human Serum using a Hippocampal Neuronal Culture

Over the recent years, live cell-based assays have been used successfully to detect antibodies against surface and conformational antigens. Here, we describe a method using high-throughput flow cytometry enabling the analysis of large cohorts of patients. Detection of novel antibodies will improve diagnosis and treatment of immune-mediated disorders.

High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum

We describe here a method to generate customizable antigen microarrays that can be used for the simultaneous detection of serum IgG and IgM autoantibodies from humans and mice. These arrays allow for high-throughput and quantitative detection of antibodies against any antigens or epitopes of interest.

Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies

DFS70 autoantibodies mimic common disease-associated antinuclear antibody patterns making accurate interpretation challenging when using conventional HEp-2 substrates. The protocol describes advantages of novel engineered HEp-2 substrate over conventional HEp-2 in ANA screening and distinguishing DFS70 patterns with high confidence in both monospecific and mixed ANA positive cases.

Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate

The goal of this protocol is to facilitate the study of NMDA-receptors (NMDAR) at a larger scale and allow the examination of modulatory effects of small molecules and their therapeutic applications.

A High-throughput Calcium-flux Assay to Study NMDA-receptors with Sensitivity to Glycine/D-serine and Glutamate

Cell-based assay is a widely used method to detect serum anti-aquaporin-4 immunoglobulin G. This method could be applied to clinical diagnosis and scientific researches of neuromyelitis optical spectrum disorders.

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay

We model a simple multiplexed ECL assay that combines 7 autoantibody assays together. The assay is capable of screening for T1D and multiple other autoimmune diseases, simultaneously, including celiac disease, autoimmune thyroid disease, and autoimmune polyglandular syndrome 1.

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Autoimmune encephalitis is a new category of antibody-mediated diseases of the central nervous system. Hippocampal neurons can be used to discover and characterize these antibodies. This article provides a protocol for primary cell culture and immunostaining to determine autoantibodies in the serum and cerebrospinal fluid of patients.

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis

Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS), which shares with the human disease a robust humoral autoimmune response. Here, we report a simple and flexible ELISA protocol to quantify autoantibodies in the serum of EAE immunized mice.

Quantification of Autoreactive Antibodies in Mice upon Experimental Autoimmune Encephalomyelitis

We provide a step-by-step immunocytochemistry (ICC) methodology for detecting anti-MDA5. This approach involves cell fixation, permeabilization, antibody incubation, and imaging techniques, which allow for the accurate detection of anti-MDA5 autoantibodies, aiding in the diagnosis of rapidly progressing interstitial lung disease in myositis patients.

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

We describe a recently developed immunoassay platform based on the principles of cell-free synthetic biology and the dot-blot technique for customizable detection of antibody response in human and animal sera.

Cell-Free Dot Blot as a Practical and Adaptable Immunoassay Platform for the Detection of Antibody Response in Human and Animal Sera

Learn a cell-based immunofluorescence assay to detect NMDA receptor autoantibodies in blood using HEK293 cells expressing NR1-GFP. This method provides a simple screening tool for autoimmune encephalitis diagnosis.

A Simple Cell-based Immunofluorescence Assay to Detect Autoantibody Against the N-Methyl-D-Aspartate (NMDA) Receptor in Blood

Explore More Videos